Evolocumab administration prior to Coronary Artery Bypass Grafting in patients with multivessel coronary artery disease (EVOCABG): study protocol for a randomized controlled clinical trial

[1] Gummert JF(2009)Cardiac Surgery in Germany during 2008. A report on behalf of the german society for thoracic and cardiovascular surgery Thorac Cardiovasc Surg 57 315-323

[2] Funkat A(2016)Outcomes in patients undergoing coronary artery bypass graft surgery in the United States based on hospital volume, 2007 to 2011 J Thorac Cardiovasc Surg 151 1686-1692

[3] Beckmann A(2009)Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease N Engl J Med 360 961-972

[4] Schiller W(2013)A contemporary cost analysis of postoperative morbidity after coronary artery bypass grafting with and without concomitant aortic valve replacement to improve patient quality and cost-effective care Ann Thorac Surg 96 1621-1627

[5] Hekmat K(2002)Fundamentals of reperfusion injury for the clinical cardiologist Circulation. 105 2332-2336

[6] Ernst M(2020)Statin reload before off-pump coronary artery bypass graft: Effect on biomarker release kinetics Ann Card Anaesth 23 27-33

[7] Kim LK(2008)Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial J Thorac Cardiovasc Surg 136 1541-1548

[8] Looser P(2004)Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery Circulation. 110 II45-II49

[9] Swaminathan RV(2016)Perioperative Rosuvastatin in Cardiac Surgery N Engl J Med 374 1744-1753

[10] Minutello RM(2001)Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA. 286 64-70

[1] Gummert JF(2009)Cardiac Surgery in Germany during 2008. A report on behalf of the german society for thoracic and cardiovascular surgery Thorac Cardiovasc Surg 57 315-323

[2] Funkat A(2016)Outcomes in patients undergoing coronary artery bypass graft surgery in the United States based on hospital volume, 2007 to 2011 J Thorac Cardiovasc Surg 151 1686-1692

[3] Beckmann A(2009)Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease N Engl J Med 360 961-972

[4] Schiller W(2013)A contemporary cost analysis of postoperative morbidity after coronary artery bypass grafting with and without concomitant aortic valve replacement to improve patient quality and cost-effective care Ann Thorac Surg 96 1621-1627

[5] Hekmat K(2002)Fundamentals of reperfusion injury for the clinical cardiologist Circulation. 105 2332-2336

[6] Ernst M(2020)Statin reload before off-pump coronary artery bypass graft: Effect on biomarker release kinetics Ann Card Anaesth 23 27-33

[7] Kim LK(2008)Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial J Thorac Cardiovasc Surg 136 1541-1548

[8] Looser P(2004)Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery Circulation. 110 II45-II49

[9] Swaminathan RV(2016)Perioperative Rosuvastatin in Cardiac Surgery N Engl J Med 374 1744-1753

[10] Minutello RM(2001)Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA. 286 64-70